Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Berkeley
About this trial
The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
Eligibility criteria
Qualifiers
Is 18 years of age and has full legal capacity to volunteer (no max age requirement)
Baseline Ocular Surface Disease Index (OSDI) >13
Has mild to moderate MGD
Has best corrected visual acuity of 20/40 or better
Disqualifiers
Is participating in any other type of clinical or research study
Is currently pregnant, nursing, lactating, or planning a pregnancy
Is currently having >50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD)
Is currently using any topical ocular medications
Trial design
Treatments tested in this trial
- Varenicline 0.03Mg/Spray Nasal Soln
Treatment groups
65 Participants
are divided into 1 treatment groupLocations
1U.C. Berkeley Clinical Research Center94720, BerkeleyCalifornia, United States
Sponsors and collaborators
University of California, Berkeley
Lead sponsor
Viatris Inc.
Collaborator
Source ClinicalTrials.gov